Document Detail

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.
MedLine Citation:
PMID:  19153117     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Insulin-like growth factor receptor-1 (IGFR-1) represents a novel molecular target in non-small-cell lung cancer (NSCLC). IGFR-1 and epidermal growth factor receptor (EGFR) activation is essential to mediate tumor cell survival, proliferation and invasion. We explored the correlation between IGFR-1 and EGFR, their relationship with clinicopathological parameters and their impact on outcome in resected stage I-III NSCLC patients. PATIENTS AND METHODS: Tumors from 125 surgical NSCLC patients were evaluated for IGFR-1 and EGFR expression by immunohistochemistry. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. RESULTS: IGFR-1 protein overexpression was detected in 36.0% of NSCLC patients and was associated with larger tumor size (P = 0.04) but not with other clinical or biological characteristics. EGFR protein overexpression was observed in 55.2% of NSCLC, more frequently in squamous cell carcinoma (SCC) than non-SCC (63.7% versus 36.3%, chi(2) = 9.8, P = 0.001). IGFR-1 protein expression was associated with EGFR protein expression (P = 0.03). At the multivariate analysis, high coexpression of both IGFR-1 and EGFR was a significant prognostic factor of worse disease-free survival (DFS) (hazard ratio 2.51, P = 0.01). CONCLUSION: A statistically significant association was observed between high coexpression of both IGFR-1 and EGFR and worse DFS in early NSCLC patients.
V Ludovini; G Bellezza; L Pistola; F Bianconi; L Di Carlo; A Sidoni; A Semeraro; R Del Sordo; F R Tofanetti; M G Mameli; G Daddi; A Cavaliere; M Tonato; L Crinò
Related Documents :
11965607 - Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
3283457 - Prognostic significance of estrogen and progesterone receptors in stage ii breast cancer.
3368797 - Quantitative estrogen and progesterone receptor levels related to progression-free inte...
20148717 - Therapeutic targeting of egfr in malignant gliomas.
8103417 - The assessment of proliferating cell nuclear antigen immunohistochemical staining in sm...
11023237 - Electron microscopy of squamous cell carcinoma of the head and neck.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-01-19
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  20     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-30     Completed Date:  2009-06-02     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  842-9     Citation Subset:  IM    
Division of Medical Oncology, Public Hospital, Perugia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / chemistry,  mortality,  pathology,  surgery*
Disease-Free Survival
Kaplan-Meiers Estimate
Lung Neoplasms / chemistry,  mortality,  pathology,  surgery*
Lymph Node Excision
Middle Aged
Neoplasm Staging
Proportional Hazards Models
Receptor, Epidermal Growth Factor / analysis*
Receptor, IGF Type 1 / analysis*
Retrospective Studies
Risk Assessment
Time Factors
Treatment Outcome
Tumor Markers, Biological / analysis*
Reg. No./Substance:
0/Tumor Markers, Biological; EC protein, human; EC, Epidermal Growth Factor; EC, IGF Type 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in ...
Next Document:  Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.